Pasithea Therapeutics Includes Esketamine Nasal Spray to Clinical Offerings in U.K.
Pasithea Therapeutics Corp. (NASDAQ: KTTA) has reported that its subsidiary, Pasithea Clinics has been approved to provide Esketamine Nasal Spray (SPRAVATO) for treatment resistant depression in adults and has begun offering treatment in Knightsbridge, London loation. Three clinics in the...